5-year overall survival ( 95 % [ 95 % CI 93-97 ] vs 86 % [ 83-89 ] ; HR 248 [ 95 % CI 131-468 ] ; p = 0009 ) and 5-year metastasis-free survival ( 94 % [ 95 % CI 92-96 ] vs 83 % [ 80-86 ] ; HR 231 [ 95 % CI 123-385 ] ; p = 001 ) were also significantly better in the long-term androgen deprivation group than in the short-term androgen deprivation group .